Key Takeaways
- • Shah Capital, holding a 9% stake and serving as Novavax's second-largest shareholder, announced opposition to the re-election of all board members and the executive compensation plan at the upcoming annual meeting, escalating activist pressure on the vaccine manufacturer.
- • The hedge fund's founder Himanshu Shah called for a 30% reduction in senior leadership, board downsizing from eight to five members, and a share repurchase program of 10–20 million shares to address what he characterized as ineffective management and strategic direction.
- • Shah Capital is urging the company to consider bringing in a long-term strategic investor with a 10–20% stake and has criticized the Sanofi collaboration, citing delays in late-stage COVID/influenza combination vaccine results for a market worth over $5 billion.
- • Novavax stock rose between 4% and 7.6% following the announcement, though Shah indicated he is not currently pursuing a proxy fight due to the entrenched board structure, instead appealing to proxy advisors ISS and Glass Lewis to reconsider their support for management.
- • Novavax responded by emphasizing ongoing R&D investment and cost-saving initiatives while highlighting partnerships with Pfizer and progress toward Sanofi collaboration, despite acknowledging strategic and debt management challenges.
Summary
Shah Capital has escalated its activist campaign against Novavax, signaling opposition to the biotech company's board and executive compensation at the forthcoming annual meeting. With a 9% stake making it the second-largest shareholder, the hedge fund is leveraging significant influence to force strategic reconsideration at the vaccine maker.
In a letter cited by Reuters, Shah Capital founder Himanshu Shah outlined a comprehensive critique of current management, calling the leadership's strategic approach "lacking conviction." Shah demanded a 30% reduction in senior leadership headcount and a board contraction from eight to five members. The activist investor also pressed Novavax to execute a share repurchase of 10–20 million shares and to recruit a long-term strategic partner holding a 10–20% stake to help reshape corporate direction and governance. Shah's language was pointed, describing the letter as "an indictment of the leadership."
A central concern for Shah Capital is Novavax's partnership strategy, particularly the collaboration with Sanofi on a COVID/influenza combination vaccine targeting a market estimated at over $5 billion. Shah criticized the arrangement for delivering limited benefits while citing delays in Sanofi's late-stage trial results. The activist has previously suggested Novavax consider strategic alternatives, including a potential sale, though he clarified this week that he is not initiating a proxy contest given the entrenched eight-member board structure he views as resistant to change.
Rather than a proxy fight, Shah is appealing to institutional proxy advisory firms ISS and Glass Lewis to reconsider their recommendations supporting the board and compensation proposals. Novavax responded with a statement reaffirming its commitment to R&D investment while underscoring cost-reduction measures already underway and highlighting partnerships with Pfizer and ongoing Sanofi collaboration efforts.
Market reaction was positive, with Novavax shares gaining 4% to $8.32 in initial trading, though supplemental reporting indicated a larger intraday gain of approximately 7.6%, suggesting investor appetite for the activist pressure and potential operational changes at the vaccine maker.
In a letter cited by Reuters, Shah Capital founder Himanshu Shah outlined a comprehensive critique of current management, calling the leadership's strategic approach "lacking conviction." Shah demanded a 30% reduction in senior leadership headcount and a board contraction from eight to five members. The activist investor also pressed Novavax to execute a share repurchase of 10–20 million shares and to recruit a long-term strategic partner holding a 10–20% stake to help reshape corporate direction and governance. Shah's language was pointed, describing the letter as "an indictment of the leadership."
A central concern for Shah Capital is Novavax's partnership strategy, particularly the collaboration with Sanofi on a COVID/influenza combination vaccine targeting a market estimated at over $5 billion. Shah criticized the arrangement for delivering limited benefits while citing delays in Sanofi's late-stage trial results. The activist has previously suggested Novavax consider strategic alternatives, including a potential sale, though he clarified this week that he is not initiating a proxy contest given the entrenched eight-member board structure he views as resistant to change.
Rather than a proxy fight, Shah is appealing to institutional proxy advisory firms ISS and Glass Lewis to reconsider their recommendations supporting the board and compensation proposals. Novavax responded with a statement reaffirming its commitment to R&D investment while underscoring cost-reduction measures already underway and highlighting partnerships with Pfizer and ongoing Sanofi collaboration efforts.
Market reaction was positive, with Novavax shares gaining 4% to $8.32 in initial trading, though supplemental reporting indicated a larger intraday gain of approximately 7.6%, suggesting investor appetite for the activist pressure and potential operational changes at the vaccine maker.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.